Working together to defeat the COVID pandemic

Welcome to the UCSF Office of Research COVID-19 central clearinghouse for all UCSF COVID-19 related research and funding opportunities.

UCSF researchers responded quickly and continue to address the challenges that the COVID-19 pandemic has brought forth. Their investigations range from fundamental virology, immunology, epidemiology, diagnostic development, drug target identification, therapeutic development and testing, development of animal models, medical interventions, socio-behavioral impacts, computational modelling, and clinical implementation.

Created by the UCSF Office of Research and research stakeholders, this website is dedicated to encouraging and supporting COVID-19 and SARS-CoV-2 research collaboration on campus and within the global research community, as well as promoting targeted resources and housing funding opportunities aimed at COVID-19 and SARS-CoV-2. Our goal is to serve as both a single central resource for the UCSF research community to find all of the information they need to build connections, find funding, and generate new knowledge in this critical time as well as an overarching view of the spectrum of scientific discovery currently in progress at UCSF in these two areas.

Members of the public are invited to learn about the range of our current research-in-progress and explore specific projects as well as opportunities to participate in clinical trials. Thank you for your interest in UCSF research.

UCSF researchers are encouraged to consider new and innovative cross-disciplinary collaborations. Researchers can take a deep dive into our work, finding detailed information on UCSF-based COVID-19 related research projects by topic, contact information for lead PIs, and funding opportunities. This information is available via MyAccess (see main menu Login link).

Funding Highlights

NIH Will Continue to Accept Preliminary Data as Post-Submission Material Through August/October 2021 Councils (October 21, 2020):

In recognition of the fact that COVID-19 may still be adversely affecting the ability of applicants to generate preliminary data, NIH will continue to accept a one-page update with preliminary data as post-submission materials for applications submitted for the August/October 2021 council (beginning with applications submitted for the January 25, 2021 due date for Summer 2021 review meetings), ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application (NOT-OD-20-179). The deadline for submitting all post-submission materials, including preliminary data, will be 30 days before the study section meeting. Because applications for emergency competitive revisions and urgent competitive revisions undergo expedited review, post-submission materials will not be accepted for those applications.

COVID-19 related research funding summary:

The Office of Sponsored Research reports the following summary of COVID-19 related proposals and awards as of January 19:

  • Total proposals: 588
  • Total requested: $672,047,350
  • Total awards: 204
  • Total awarded: $153,096,020

Excerpted highlights from the most recent UCSF Division of HIV, Infectious Diseases & Global Medicine Cross-Campus Infectious Diseases COVID-19 Task Force weekly digest:

As of January 15, 2021



Where are doses?

As of this week in the US, over 29 million doses of the Pfizer BioNtech and Moderna vaccines have been distributed primarily to health care workers and residents of long-term care facilities. However, only ~10 million of distributed doses have been given. 4.5 million doses have been allocated to long-term care facilities and ~1 million doses have been given. In California, 891,000 (26%) of the 3.4 million doses distributed to the state have been given. Vaccine rollout in the United States is much slower than had been hoped and California ranks 41 among states in terms of percent of vaccine available injected. The initial round of vaccine distribution has been primarily through hospitals and other institutional health-care settings. The next phase will draw more on pharmacies and health clinics to access high-risk patients.

Vaccines details

The Pfizer BioNtech mRNA, 2-dose vaccine was approved for Emergency Use Authorization (EUA) by FDA on December 11, 2020 and recommended for persons ≥ 16 years given its high level of efficacy. Broad distribution of this vaccine has been underway in the US and in over a dozen countries worldwide. Several cases of anaphylaxis following administration of the Pfizer BioNtech vaccine were reported in Europe, the CDC recently shared data from their Vaccine Adverse Event Reporting System in the US between December 14–23, 2020. They identified 21 cases of anaphylaxis after administration of 1,893,360 first doses (11.1 cases per million doses); 71% of these occurred within 15 minutes of vaccination.

The Moderna mRNA, 2-dose vaccine was approved for Emergency Use Authorization (EUA) by FDA on December 18, 2020 and recommended for persons ≥ 18 years given its high level of efficacy. 18 million doses have been supplied to the US and it has received approval in Canada, EU, and Israel. Distribution in the United States is ongoing. Moderna stated this week that immunity from the COVID-19 vaccine should last at least a year although they did not provide data to support the statement. A trial of the vaccine in adolescents is ongoing.

The AstraZeneca adenovirus vector, 2-dose vaccine was approved for limited distribution in the United Kingdom, India and several other countries after publication of data from Phase 2/3 studies. This vaccine has not been approved in the US and a large phase 3 study is underway in the US which has fully enrolled, with preliminary data anticipated in February.

Johnson and Johnson reported the results of a Phase 1/2a study of both single-dose and two-dose, adenovirus vector in younger and older adults. Neutralizing antibody titers against wild-type virus were detected in >90% of participants on day 29 after the first vaccine dose and 100% by day 57. Although the study had been halted following an adverse reaction in a study volunteer, it was resumed shortly after and adverse events have not been significant. A phase 3 trial of a single dose vaccine is nearing completion.

Immunity to COVID-19 infection or vaccination likely long-lived

The immune response to COVID-19 after infection encompasses all arms of adaptive immunity: antibodies (from B cells), memory B cells, and memory T cells (both CD4+ and CD8+ cells). However, the duration and spectrum of immunity after COVID-19 is unknown, mainly because SARS-CoV-2 is a new infection. Immune memory, from either infection or vaccination, is the source of protective immunity from a subsequent infection and needs systematic analysis. A recent study assessed immune memory of all three branches of adaptive immunity among 188 (80 male; 108 female) patients recovered from COVID-19 (93% mild; 7% hospitalized) over 8 months. Longitudinal samples assessed circulating antibodies, memory B cells, CD8+ T cells, and CD4+ T cells specific for SARS-CoV-2 over 8 months. Memory B cells specific for the spike protein or receptor binding domain (RBD) were detected in almost all COVID-19 cases, with no apparent half-life at 5 to 8 months post-infection. Memory T cell half-lives were also long, observed over 6 months in this cohort (~125-225 days for CD8+ and ~94-153 days for CD4+ T cells), comparable to the 123 days half-life observed for memory CD8+ T cells after yellow fever immunization (a vaccine usually given once over a lifetime). Antibodies against the spike protein and RBD were also durable, with modest declines over time.

Conclusion: This longitudinal and comprehensive analysis of memory T and B cell responses to COVID-19 after infection was heartening in term of the likely durability of immune memory after either natural infection or vaccination for SARS-CoV-2.


Explore COVID-19 research at UCSF

Learn more


Discover support for COVID-19 research

Learn more


Find partners and tools for projects

Learn more


UCSF COVID-19 Publications

List of publications & recent "Hot Pubs"

Learn more

Guidelines & Policies

COVID-19 related research guidelines & policies

Learn more

Task Force

COVID-19 Research Coordination Task Force

Learn more